These results, and those of the in vitro experiments, suggest that the therapeutic effects of BTZO-15 in animal models of IBD are based on increases in HO-1 and GST Ya levels via ARE activation in rectum, not suppression of cytokine production, although further studies will be needed to clarify the precise mechanisms of action. This evidence concerns the gene HMOX1 and inflammatory bowel disease.